Enanta Pharmaceuticals (ENTA) Non Operating Income (2012 - 2026)

Enanta Pharmaceuticals has reported Non Operating Income for 15 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 313.15% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$1.5 million (down 146.91% YoY), and the FY2025 full-year result was $1.8 million, down 53.88% from the prior year.
• Non Operating Income for Q1 2026 stood at -$1.2 million, down from -$661000.0 in the prior quarter.
• The five-year high for Non Operating Income was $1.9 million in Q2 2023, with the low at -$1.2 million in Q1 2026.
• Historically, Non Operating Income has averaged $669647.1 across 5 years, with a median of $714000.0 in 2022.
• Annual changes were most pronounced in 2023 — Non Operating Income surged 620.39% — and 2026, when it slumped 313.15%.
• Enanta Pharmaceuticals' Non Operating Income stood at $993000.0 in 2022, then decreased by 13.7% to $857000.0 in 2023, then declined by 2.33% to $837000.0 in 2024, then plunged by 178.97% to -$661000.0 in 2025, then slumped by 86.38% to -$1.2 million in 2026.
• The last three Non Operating Income figures came in at -$1.2 million (Q1 2026), -$661000.0 (Q4 2025), and -$282000.0 (Q3 2025), per Business Quant data.